3SBio Inc (3SBio) is a fully integrated biotechnology company that carries out the research, development, manufacturing, and marketing of biopharmaceutical products in China. It provides products for the treatment of cancer, autoimmunity, nephrology, dermatology, diabetes, and other diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

3SBio's research and development (R&D) efforts focus on developing novel medicines for patients in China and other countries. Its R&D focuses on developing product candidates in two core treatment areas, cancer, and nephrology. 3SBio’s integrated R&D expertise spans the discovery and development of biopharmaceutical products including gene expression, molecular cloning, cell line construction, process development, design and management of clinical and pre-clinical trials, manufacturing process development and analytical process development for quality control and assurance. It has experience in the R&D of both mammalian cell-expressed and bacterial cell-expressed biopharmaceuticals. In FY2022, the company incurred R&D expenses of CNY693.2 million, which as a percentage of revenue stood at 10.1%. 3SBio has three R&D platforms, namely, a mammalian cell-based platform, a chemical platform, and a bacterial cell-based platform. As of December 31, 2022, the company had a pipeline of 31 product candidates in cancer, dermatology, nephrology and auto-immune diseases and other areas. Of these 31 product candidates, 16 are antibodies, six are other biologic products, and nine are small molecules. Specifically, there are seven products for treating cancer, 13 for autoimmune diseases like rheumatoid arthritis, refractory gout, and AMD, nine for nephrology, and two for dermatology.